Sheep CD34+ Amniotic Fluid Cells Have Hematopoietic Potential and Engraft After Autologous In Utero Transplantation

S. W. Steven Shaw,[a,b,c] Michael P. Blundell,[d] Caterina Pipino,[a] Panicos Shangaris,[a,b] Panagiotis Maghsoudlou,[a] Durrgah L. Ramachandra,[a] Fanos Georgiades,[a] Michael Boyd,[e] Adrian J. Thrasher,[d] Christopher D. Porada,[f] Graça Almeida-Porada,[f] Po-Jen Cheng,[c] Anna L. David,[b] Paolo de Coppi[a,g]

Key Words. Sheep CD34 • Amniotic fluid stem cells • Autologous transplantation • Cell therapy

[a]Stem Cells and Regenerative Medicine Section, Institute of Child Health, [b]Prenatal Cell and Gene Therapy Group, Institute for Women's Health and [d]Molecular Immunology Unit, Institute of Child Health, University College London, London, United Kingdom; [c]Department of Obstetrics and Gynaecology, Chang Gung Memorial Hospital at Linkou and Chang Gung University, College of Medicine, Taoyuan, Taiwan; [e]Biological Surgical Unit, Royal Veterinary College, London, United Kingdom; [f]Wake Forest Institute for Regenerative Medicine, Winston-Salem, North Carolina, USA; [g]Great Ormond Street Hospital NHS Trust, London, United Kingdom.

Correspondence: Paolo de Coppi, M.D., Ph.D., Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, U.K. Telephone: 44-20-7905-2641; Fax: 44-20-7404-618; e-mail: p.decoppi@ucl.ac.uk; or Anna David, M.D., Ph.D., Prenatal Cell and Gene Therapy Group, Institute for Women's Health, University College London, London WC1E 6HX, U.K. Telephone: +44-20-7679-6651; Fax: +44-20-7383-7429; e-mail: a.david@ucl.ac.uk

ABSTRACT

Unmatched allogeneic in utero stem cell transplantation (IUSCT) produces poor engraftment unless the fetus has congenital immunodeficiency, probably because of maternal and fetal immune responses to injected cells. We studied the functional hematopoietic potential of transduced green fluorescent protein (GFP+) sheep amniotic fluid (AF) stem cells, before and after autologous IUSCT. CD34+ cells were selected from first trimester sheep AF, transduced overnight, and injected intravenously into NOD-SCID-gamma (NSG) mice. At 3 months, primary recipient bone marrow (BM) was injected into secondary NSG recipients. GFP+ cells were detected in the hematopoietic organs and peripheral blood of primary and secondary recipients at 3 months. Autologous IUSCT (transduced GFP+CD34+AF) was performed in fetal sheep. Six months postnatally, lamb BM was injected into secondary NSG recipients. GFP+ cells were detected in the peripheral blood of primary and secondary recipients. This confirms the hematopoietic potential of AF stem cells supporting the concept of autologous IUSCT to treat congenital hematopoietic disease. STEM CELLS 2015;33:122–132

INTRODUCTION

In utero stem cell transplantation (IUSCT) aims to provide the fetus with therapeutic cells to correct prenatal congenital diseases. Besides the obvious advantage of preventing the development of pathology in utero and thus avoiding postnatal complications, intervening during fetal life has a stoichiometric advantage, allowing the transplantation of much larger cell doses on a per kilogram basis than can be achieved postnatally [1]. Finally, the maturation of the immune system during the fetal life allows new antigens to be introduced early in gestation without rejection, and can induce immunologic tolerance to these new antigens [2].

Despite all the above, results of allogeneic IUSCT [3] in humans have been successful only for the treatment of congenital severe combined immunodeficiency (SCID) [4]. Allogeneic mesenchymal stem cells (MSCs) injected into fetuses affected with osteogenesis imperfecta successfully engrafted in only two out of five cases [4]. Attempts to treat other diseases such as sickle cell disease [5] or metabolic storage disorders for example have been unsuccessful.

In the last few years work conducted by Flake and colleagues [6] has demonstrated that this may be at least partially explained by the migration of the in utero injected cells into the maternal circulation and mounting of a rejection response, which could diminish the engraftment. This is most likely due in mice to activated maternal T cells which can cross the placenta in mice and destroy engrafted allogeneic cells [7]. In order to avoid this response, stem cells matched to the fetus or even the mother could be used. Fetal mice injected with congenic hematopoietic stem cells (HSCs), for example, all maintained stable, long-term, multilineage chimerism compared with fewer than 20% of allogeneic recipients [8].

Alternatively, in monogenic disease, stem cells derived from the fetus itself could be used after genetic modification for treatment of a fetus affected by a congenital disease. Fetal stem cells can be easily derived during pregnancy from the amniotic fluid (AF) [9–11]. In particular, ckit+ amniotic fluid stem cells are characterized by long-term self-renewal, clonal properties, and differentiation capabilities which defined them at a prepluripotent status [9, 12, 13]. They share with embryonic

Figure 1. Experimental design. Transduced sheep eGFP+ CD34+ selected fresh or frozen AF and adult BM cells were transplanted into immunocompromised NOD-SCID-gamma (NSG) mice (primary and secondary xenogeneic transplantation). Transduced sheep eGFP+CD34+ fresh AF cells were also injected into donor sheep fetuses (in utero autologous transplantation) that were subsequently delivered and followed for up to 3 months of age. Bone marrow from these primary sheep recipients was then used to perform xenogeneic secondary transplantation into NSG mice. Abbreviations: AF, amniotic fluid; BM, bone marrow.

stem cells the expression of some stem markers (e.g., OCT4 and SSEA4), but they are not tumorigenic unless reprogrammed as induced pluripotent stem cells [14].

Using a sheep model we have previously shown the potential of transduced AF mesenchymal stem cells (AFMSCs) for autologous IUSCT [15]. After first trimester amniocentesis, AFMSCs could be isolated, cultured, transduced, and transplanted back into the donor fetus as an in utero autologous transplant. Engraftment of green fluorescent protein (GFP) transduced cells was detected 2 weeks after transplantation in various tissues and organs. The sheep was the first animal model in which IUSCT was studied, using fetal liver-derived HSC as an allogeneic transplantation into normal sheep fetuses. This resulted in a multilineage hematopoietic chimerism that persisted for many years and ranged from 10% to 15% donor cell expression [16, 17]. The human-to-sheep model of IUSCT has proven to be an invaluable tool in the identification, characterization, and quantification of human HSC from several sources and this xenograft model of human hematopoiesis can serve as an accurate model to study in vivo mobilization of human HSCs [18–20].

In this study, we hypothesized that cells with hematopoietic potential were also present in sheep AF and could be used for autologous IUSCT. We used a recently developed novel sheep-specific CD34 antibody that identifies hematopoietic stem cells in the adult sheep bone marrow (BM) [21]. After selecting CD34+ cells from the AF, we transplanted them into NOD-SCID-gamma (NSG) immunocompromised mice to study their engraftment, and into donor fetal sheep after gene marking them using a viral vector for autologous IUSCT. For the first time, we have demonstrated that AF-derived cells from a large animal (sheep) possess hematopoietic potential in xenotransplanted mice, and can mediate long-term engraftment after autologous IUSCT in the sheep.

MATERIALS AND METHODS

All procedures on animals were conducted in accordance with U.K. Home Office regulations and Guidance for the Operation of Animals (Scientific Procedures) Act (1986) (Figure 1).

Sheep Animal Procedures

Time-mated Romney breed ewes were used. Eight fetuses from four ewes provided first trimester AF (300–700 ml, 60–64 days of gestation) that was collected at post-mortem examination under sterile conditions and frozen, for later use in transplantation experiments into NSG mice. Ten fetuses from five ewes were used for in utero autologous transplantation experiments. Here, general anesthesia was induced with Ketamine (4 mg/kg, Merial, London, UK, www.merial.co.uk) intravenously, and after intubation, the ewes were maintained on Isoflurane-Vet 3% (Merial, London, UK, www.merial.co.uk) in oxygen. Fetal measurements were confirmed by ultrasound [22]. The first procedure, ultrasound-guided amniocentesis, was performed in the first trimester (60–64 days of gestation, term = 145 days) using a 22 Gauge, 15 cm echo-tip needle (Cook Medical, London, UK, www.cookmedical.com). AF (10 ml) was withdrawn from each amniotic sac. Two days later, ewes were reanesthetized as above for the second procedure, an ultrasound-guided intraperitoneal injection of freshly isolated and transduced CD34+ amniotic fluid stem (AFS) cells (2×10^4, 1–2 ml) into the donor fetus using a 22-gauge 15 cm echo-tip disposable needle (Cook Medical, London, UK, www.cookmedical.com). To ensure correct needle placement within the peritoneal cavity, the needle was inserted through the ventral abdominal wall of the fetal sheep cranial and lateral to the fetal bladder to avoid the umbilical arteries. Microbubbles observed moving within the peritoneal cavity as the cells were instilled confirmed correct needle placement. Following recovery of the ewe, fetal wellbeing and standard measurements of growth (occipital snout length, biparietal diameter, femur length, and abdominal circumference) were measured every 20 days until birth [22].

At birth, lambs were weighed and measured (girth at umbilicus, biparietal diameter, standing height to shoulder) and assessed for wellbeing (time to standing, heart rate, respiratory rate, temperature, and oxygen saturation). Lambs were fed naturally with ewe breast milk. Lamb peripheral blood was collected from the jugular vein (No. 18 needles with 20 ml syringe) at birth and every 2 weeks thereafter for flow

cytometry analysis. Data on lamb growth and wellbeing were collected regularly until scheduled post-mortem examination at 6 months of age. This was performed under general anesthesia to allow sterile collection of lamb BM from multiple sites (sternum, femur, humerus, and iliac crest) using a trocar needle, and sampling from all internal organs. Ewes underwent a scheduled post-mortem examination with extensive tissue sampling at 3 months after birth once weaning was completed.

Isolation and Characterization of Sheep CD34+ AFS Cells and Adult BM Cells

Fresh sheep CD34+AFS cells were selected using a sheep-specific primary monoclonal IgG1 CD34 antibody [21] immediately after fluid collection using MACS system (Miltenyi Biotec, Bergisch Gladbach, Germany, www.miltenyibiotec.com). The primary CD34 antibody was incubated with sheep AF total cells for 15 minutes on ice (1:100 concentration). After washing out the primary antibody, the secondary antibody (rat anti-mouse IgG1 MicroBeads, Miltenyi Biotec, Bergisch Gladbach, Germany, www.miltenyibiotec.com) was incubated with the previous cell suspension for15 minutes on ice (1:100 concentration). Before sorting, the median size columns were rinsed with phosphate buffered saline (PBS) with 0.5% bovine serum albumin (BSA). The CD34+ fraction of cells conjugated with microbeads was collected after washing three times with PBS. Adult sheep BM collected from the sternum was washed by passing through a cell strainer with PBS, and CD34+ cells were selected as described above for AFS. Sheep CD34+AFS or BM cells were prepared as single-cell suspensions in PBS and counted. Fresh unsorted sheep AF cells were frozen down in fetal bovine serum (FBS) (90%) and dimethyl sulfoxide (DMSO) (10%) in liquid nitrogen for 3–6 months before NSG mice transplantation experiments and thawed for CD34+ sorting and transplantation. Sorted CD34+ cells were characterized using sheep-specific surface antibodies including fluorescein isothiocyanate (FITC) or phycoerythrin (PE) conjugated CD14, CD31, CD44, CD58, CD34, and CD45 (AbD Serotec, London, UK, www.abdserotec.com) by flow cytometry.

Culture and Viral Transduction of Sheep CD34+AFS or BM Cells

Frozen CD34+AFS or BM cells were used immediately after thawing. The cell suspension was centrifuged at 1,500 rpm for 5 minutes, the supernatant was discarded, and the thawed cells were resuspended in culture medium for viral transduction. Fresh or thawed CD34+AFS or thawed CD34+BM cells were transduced for 48 hours with a lentivector encoding the HIV-1 central polypurine tract element, the Spleen Focus Forming Virus LTR promoter, and the marker gene eGFP, at multiplicity of infection (MOI) = 50 as previously described [15]. The culture medium contained basal Iscove's Modified Dulbecco's Media (IMEM), 10% FBS, and StemSpan CC100, which contains a combination of cytokines including Flt-3, Stem cell factor, IL3, and IL6 (Stem Cell Technologies, Manchester, UK, www.stemcell.com). Fresh or frozen CD34+ AFS or frozen CD34+BM cells (1×10^5) were seeded in 24-well low attachment plates with culture medium for 48 hours (37°C, 5% CO_2). The lentivector (10 μl, MOI = 50) was added while seeding the cells into each well. After 48 hours of viral transduction, the cell suspension was washed and resuspended in PBS for in utero autologous injection or NSG mice injection.

Xenotransplantation of NOD-SCID Gamma Mice and Collection of Peripheral Blood and Organs

NSG mice, up to 12 weeks of age, were sublethally irradiated (3 Gy) 1 hour prior to xenotransplantation. Sheep fresh or frozen CD34+AFS cells, or adult CD34+BM cells (3×10^5 in 0.2 ml PBS using 0.5 ml insulin syringe with $27\frac{1}{2}$ gauge needle) (BD, London, UK, www.bd.com) were injected into the tail vein of primary or secondary NSG mice (Figure 1).

At 4 and 8 weeks after transplantation, NSG recipients were sedated using vaporized Isoflurane-Vet 5% in oxygen (Vet-Tech Solutions, Ltd., London, UK, www.vet-tech.co.uk), and the peripheral blood was sampled from an incision on the tail made using a scalpel (No. 11 blade). Blood (100 μl) was collected by pipette into a heparin-rinsed microcentrifuge tube. Red blood cells (RBC) lysis solution (1 ml, 5-PRIME, Inc., Nottingham, UK, www.5prime.com) was added to each blood sample for 5 minutes at room temperature. The sample was centrifuged (1,500 rpm for 5 minutes), the supernatant was removed, and the procedure was repeated with RBC lysis solution until the pellet was clean. The pellet was resuspended in 300 μl PBS for flow cytometry analysis of GFP+ cells.

At 12 weeks of age, all recipient mice were sedated (vaporized Isoflurane-Vet 5% in oxygen, VetTech Solutions, Ltd., London, UK, www.vet-tech.co.uk), and blood (0.5–1 ml) was collected via intracardiac puncture using a 22 gauge needle. The mice were sacrificed by manual dislocation of cervical cord and underwent extensive post-mortem examination and tissue harvest (liver, thymus, heart, striated muscle from thigh, lung, kidney, spleen, adrenal gland, and gonad). Femoral bones were collected for retrieval of BM. Liver and spleen samples were ground using a syringe plunger in a sterile dish, rinsed with PBS, then filtered through a cell strainer (40 μm nylon mesh, BD, London, UK, www.bd.com). The BM was flushed from the femoral bones with PBS using a 22 gauge needle with syringe and then strained. RBC lysis buffer (2 ml) was added to each sample for 10 minutes at room temperature and then centrifuged (1,500 rpm for 5 minutes). The supernatant was removed, the pellet was suspended in 300 μl PBS, and washed and centrifuged again. The supernatant was discarded and the pellet was resuspended in 300 μl PBS at 4°C for flow cytometry.

Flow Cytometry for eGFP Detection and Analysis

Single-cell suspensions of spleen, liver, and BM from the fetuses or lambs were prepared immediately following animal sacrifice by straining tissue through a 40 μm cell strainer. After rinsing with PBS, red-blood cell lysis buffer was added for 5 minutes at 37°C. Mononuclear cells were isolated from the umbilical cord and maternal blood samples by density gradient centrifugation using Ficoll-Paque solution (Stem Cell Technology, Manchester, UK, www.stemcell.com). Single-cell suspensions from control uninjected ewes and their fetuses were used as negative controls for sheep samples. Uninjected CD1 mice were used as the negative control for mice experiments. The cells were acquired on Becton Dickinson FACSCalibur and LSR II machines (Becton Dickinson, San Jose, CA, www.bd.com), and analyzed using FlowJo version 5.7.1 software (Tree Star, London, UK, www.flowjo.com). Ten thousand events were collected per sample.

eGFP+ signal was detected using FITC gating in all the organs of NSG mice, sheep, and lambs. The organs from YFP+ mice were used as a positive control. To study transduction

efficiency, the same FITC channel was used to gate the eGFP+ population, untransduced AFS cells were used as negative control, and AFS cells of Yellow Fluorescent Protein (YFP) transgenic mice were used for the positive control.

PCR for Detection of eGFP DNA

PCR to detect eGFP DNA was performed as previously described [15]. DNA from sheep AFS cells transduced with eGFP was used as a positive control.

Colony-Forming Unit Assay

MethoCult GF H4434 kit and M3434 kit (Stem Cell Technologies, Manchester, UK, www.stemcell.com) were used to perform colony-forming unit (CFU) assays for sheep CD34+AFS or BM cells and NSG mice BM cells. In CD34$^+$ cells that were isolated by MACS were added into methylcellulose cocktail containing cytokines and growth factors (1×10^4 cells per plate). The mixture was vortexed and plated into sterile 35 mm plates that were then incubated for 14 days (37°C, 5% CO_2 in humidified atmosphere). Colonies were then scored using an inverted microscope and colony-forming unit-granulocyte, erythrocyte, monocyte, megakaryocyte (CFU-GEMM), colony-forming unit-granulocyte, monocyte (CFU-G/M/GM), and burst-forming unit/CFU-erythroid (BFU/CFU-eE) were recorded.

Confocal Microscopy

Fresh sheep and mouse tissues, embedded in OCT (VWR, Leicestershire, UK, www.vwr.com), were snap frozen in methyl-butane and liquid nitrogen and were cut into 10–15 μm sections using a cryostat (OTF, Bright, Cambridgeshire, UK, www.brightinstruments.com). Blocking solution was prepared with 1% BSA, 0.15% Glycine, and 0.1% Triton in PBS and preserved at 4°C. The liver sample slides were costained with mouse monoclonal anti-GFP antibody (A11120, Invitrogen, Paisley, UK, www.lifetechnologies.com) and rabbit polyclonal anti-alpha fetoprotein (AFP) antibody (ab74663, Abcam, London, UK, www.abcam.com) at 1:100 dilution with buffer solution. Slides were incubated for 2 hours at room temperature. The secondary antibodies, Alexa Fluor 488 goat anti-rabbit IgG, and Alexa Flour 594 donkey anti-mouse IgG (A11008 and A21203, Invitrogen, Paisley, UK, www.lifetechnologies.com) were used (1:100 dilution) for another 2 hours incubation at room temperature. The sample slides were observed using confocal microscopy (Leica TCS SP5 II, Wetzlar, Germany, www.leica-microsystems.com), and the images were analyzed with the software ImageJ (NIH, Bethesda, Maryland, imagej.nih.gov/ij). The green positive signal indicated the eGFP+ cells, and the red signal indicated hepatocytes staining with AFP.

RESULTS

Sheep CD34+ AF Cells and CD34 BM Cells Both Have Hematopoietic potential

AF (mean volume 487 ml, range 300–700 ml) collected from first trimester time mated sheep ($n = 8$, mean gestational age 62 days, range 60–64) at post-mortem examination showed a mean total cell count of 6.25×10^6 (range $6–8 \times 10^6$ cells), with a similar percentage of CD34+ cells for fresh ($n = 4$) and frozen ($n = 4$) AF samples (Fig. 2A). The percentage of CD34+ cells from adult sheep BM was also similar to that in the AF (Fig. 2A, 2B). CD34+ cells derived from fresh or frozen AF, and from BM,

were seeded into semisolid culture in vitro and generated hematopoietic colonies with a similar percentage of CFU-GEMM, CFU-G/M/GM, and BFU/CFU-E (Fig. 2C, 2D). Both AF- and BM-derived CD34+ cells were positive for CD45 (96.5%, 95.1%, and 94.3% in fresh AF, frozen AF, and adult BM groups, respectively), but were negative for MSC markers including CD44 and CD58 (Fig. 2E). Moreover, the cells were also homogenously negative for CD14 (monocyte marker) and CD31 (endothelial cell marker; Fig. 2E).

Sheep CD34+ AF Cells Are Effectively Transduced with Lentiviral Vectors

Cells were transduced with a lentivector (HIV-SFFV vector encoding eGFP, 1×10^9/ml, MOI = 50) for 48 hours before transplantation. Mean transduction efficiency tested 72 hours after incubation using flow cytometry was 56.63% ± SD 11.0% (range 46.9%–73.2%, $n = 6$, Fig. 2F). There was no significant difference in transduction efficiency of cells between the three cell sources.

Transduced Sheep eGFP+ CD34+ Cells Engraft Hematopoietic Organs in NSG Mice

The experimental design is shown in Figure 1. For primary xenogeneic transplantation, sheep CD34+ containing eGFP+ and eGFP− cells from three sources (3×10^5 cells of fresh AF, frozen AF, and adult BM) was injected into NSG mice ($n = 14$; fresh AF $n = 4$, frozen AF $n = 6$, adult BM $n = 4$). Two mice that received injection of frozen AF cells died within 10 days due to poor tolerance to irradiation; the other animals survived long-term until scheduled post-mortem examination (12 out of 14, 85.7% survival). Blood samples collected from all primary transplanted NSG mice at 1 and 3 months were analyzed using flow cytometry. Blood from YFP transgenic mice was used as a positive control, while blood from an uninjected NSG mouse was the negative control. eGFP+ cells were detected in the peripheral blood at 1 month after primary xenogeneic transplantation of sheep CD34+eGFP+ frozen AF, fresh AF, or adult BM cells (mean eGFP+ cells: 3.24%, 3.48%, and 4.9%, respectively) and at 3 months (mean eGFP+ cells: 3.12%, 3.4%, and 5.26%, respectively, Fig. 3A). There was a higher percentage of eGFP+ cells detected in the peripheral blood of NSG mice injected with sheep adult BM CD34+ cells compared to sheep CD34+ cells from AF sources at 3 months ($p < .05$, ANOVA). There was no significant difference in the percentage of eGFP+ cells in NSG mice injected with frozen or fresh sheep AF CD34+ cells. At sacrifice, eGFP+ cells were detectable in the BM of all animals transplanted with frozen AF, fresh AF, and adult BM cell sources, with no significant differences detected ($n = 3$ per group, mean eGFP+ cells; 12.03%, 14.87%, and 15.87%, respectively, Fig. 3B). After culture in semisolid conditions, the number of eGFP+ colonies per high power field was significantly higher in BM cells of NSG mice that received transduced sheep CD34+ adult BM cells compared to those injected with transduced CD34+ sheep frozen, but not fresh, AF cells ($p < .05$ Fig. 3C). Besides blood and BM, eGFP DNA was detected by PCR in the liver (eight out of nine transplanted NSG mice), spleen (five out of nine), and the adrenal gland (two out of nine; Fig. 4A). There was no signal detectable in tissue samples from the heart, muscle, lung, kidney, thymus, and gonad. PCR results were confirmed by fluorescence-activated cell sorting, and showed eGFP+ cells in the spleen and liver at 3

Figure 2. Characteristics of sheep CD34+ cells from frozen and fresh AF, and from adult BM. **(A):** Proportion and **(B)** characteristics of CD34+ cells isolated from three sheep cell sources. There was no significant difference in the proportion of CD34+ cells isolated from the three cell sources. AF (frozen or fresh). Error bar: SD. **(C):** The morphology and percentage **(D)** of the three different types of hematopoietic colonies that grew in semisolid culture of sheep CD34+ AF or adult BM cells. **(E):** Example of a flow cytometry study to characterize sheep CD34+ cells from fresh AF. Cells are positive for CD45, but negative for CD14, CD31, CD44, and CD58. Red line: negative control, blue line: cells tested. **(F):** Flow cytometry showing eGFP+ cells 48 hours after lentivector (HIV.SFFV.eGFP) gene transfer to CD34+ sheep AF cells. x-axis: green fluorescent protein (GFP) channel, y-axis: cell number count, the number on the gate represents the percentage of eGFP+ positive cells out of total population. Abbreviations: AF, amniotic fluid; BFU/CFU-E, burst-forming unit/colony-forming unit-erythroid; BM, bone marrow; CFU-G/M/GM, colony-forming unit-granulocyte/monocyte/granulomonocyte; CFU-GEMM, colony-forming unit-granulocyte, erythrocyte, monocyte, megakaryocyte.

months after injection (Fig. 4B, 4C). Transplantation of transduced sheep CD34+eGFP+ adult BM cells resulted in a slighter higher engraftment rate than cells from fresh AF and frozen AF sources, in the spleen (6.7%, 5.8%, and 5.2%), and in liver (15.6%, 14.3%, and 8.5%, Fig. 4B), but this difference did not reach significance. Only in the liver, did NSG mice that received frozen AF cells show a significantly lower engraftment than the other two groups ($p < .05$, ANOVA; Fig. 4C). Immunofluorescence study showed the presence of eGFP+ cells in liver samples of all transplanted NSG mice, that were cuboid in shape, consistent with hepatocyte morphology (Fig. 4D). Costaining with alpha fetoprotein (AFP, Fig. 4E) showed a few double-stained cells providing further evidence of hepatocyte differentiation. The percentage of eGFP+ cells per high power field in liver samples was not significantly different among the three cell sources (1.2%–1.8%) (Fig. 4F).

Secondary Transplantation into NSG Mice

Secondary NSG mice were transplanted with BM cells collected from femoral bones of primary NSG mice recipients transplanted with frozen ($n = 3$) and fresh ($n = 3$) AF, and adult BM ($n = 2$) CD34+ cells at 3 months time (Fig. 2). Freshly isolated BM cells (3×10^6 per recipient) were injected into the tail vein of secondary NSG recipients. As for primary transplantation, these mice were treated with a sublethal dose of irradiation 1 hour before transplantation. Survival to scheduled post-mortem

examination at 3 months was 100%. At 1 month after transplantation, eGFP+ cells could be detected in the peripheral blood of six out of eight secondary transplanted animals (two out of three frozen AF, two out of three fresh AF, and two out of two adult BM group, Fig. 5A). There was a significantly higher level of engraftment in the peripheral blood of secondary NSG recipients that were transplanted with the BM from transduced sheep CD34+eGFP+ BM cell injected NSG primary recipients compared with frozen AF and fresh AF groups. The percentage of eGFP+ cells in the peripheral blood of secondary transplanted mice was around 2%–4%, and these levels were maintained up to the scheduled post-mortem examination at 3 months post-transplantation (Fig. 5B). Flow cytometric analysis of other hematopoietic organs 3 months after transplantation showed the presence of eGFP+ cells in the liver, spleen, and BM of the secondary NSG recipients that also had eGFP+ cells in the peripheral blood. Animals exhibiting no eGFP+ cells in their peripheral blood also showed no engraftment in liver, spleen, and BM. There were no eGFP+ cells detected in the thymus of any animals at 3 months after transplantation (Fig. 5B).

In Utero Autologous Transplantation with Sheep CD34+ AFS Cells

Time-mated pregnant ewes ($n = 5$, 10 twin fetuses) were studied (Fig. 1). The overall survival to live-birth after the

Figure 3. Analysis for engraftment of transduced sheep CD34+eGFP+ AF or adult BM cell sources in the peripheral blood and BM of primary transplanted NSG mice. **(A):** Peripheral blood engraftment. Left panel shows a representative flow cytometric dot plot of peripheral blood from NSG mice injected with frozen or fresh AF or adult BM cells, respectively. The distinct population of cells in the upper right quadrant of each graph exhibit a positive signal for eGFP. x-axis: GFP channel, y-axis: PE channel. The histogram (right panel) compares blood engraftment after injection of transduced CD34+eGFP+ sheep cells from the three sources ($n = 4$, each group) at 1 and 3 months after transplantation. There was significantly higher engraftment when the cell source was adult sheep BM (black bar) compared with cells sourced from frozen AF (light gray bar) or fresh AF (dark gray bar). Error bar: SD; *, $p < .05$; blood from YFP transgenic mice was used as a positive control while blood from uninjected NSG mice served as the negative control. **(B):** NSG mice BM engraftment. Left panel shows an example of flow cytometry to analyze engraftment of eGFP+ cells in the BM of primary NSG mouse recipients 3 months after transplantation. x-axis: eGFP+ cells, y-axis: PE channel. The distinct population of cells in the upper right quadrant of each graph exhibit a positive signal for eGFP. Negative control: BM from uninjected mice; positive control: YFP transgenic mice. The histogram (right panel) compares the percentage of eGFP+ cells in the BM of primary NSG mouse recipients of transduced sheep CD34+eGFP+ cells from the three sources ($n = 4$, each group) at 3 months after transplantation. There was no significant difference in the percentage of engraftment in the BM. The BM cells from transgenic YFP mice were used as the positive control, and bone BM cells from uninjected mice were used for the negative control. Error bar: SD. **(C):** Engrafted cells characteristics. The left panel shows the colony-forming assay to study eGFP+ cells in the BM of primary mouse NSG recipients. Positive green colonies showing characteristics of all three major progenitor cell types could be detected. Positive control: BM from a YFP mouse, Negative control: BM from uninjected mice. Upper panel: phase-contrast field; lower panel: green fluorescence signal. Bar = 100 μm. Histogram (right panel) shows the percentage of eGFP+ colonies in the BM of primary NSG recipient mice 3 months after transplantation with transduced sheep CD34+ eGFP+ cells from three cell sources. BM from NSG mice transplanted with cells from adult sheep BM had a significantly higher percentage of eGFP-positive colonies than the other two groups (*, $p < .05$, ANOVA). Error bar: SD. Abbreviations: AF, amniotic fluid; BM, bone marrow; GFP, green fluorescent protein; NSG, NOD-SCID-gamma.

operative procedure was 50% (5 out of 10). In one twin pregnancy, both fetuses miscarried within a week of the amniocentesis procedure. In another twin pregnancy, both fetuses had reduced fetal growth velocity around 100 days and were found to have died in utero at 126 days of gestation. Bacterial cultures of endometrium showed evidence of endometritis with a coliform. In a third twin pregnancy, one twin demised at 90 days of gestation, but the other continued to term and was born healthy. Fetal growth velocity was normal in all cases that survived to birth. Five lambs of three ewes were delivered at term. All lambs had normal initial assessments at birth (time to stand, heart rate, respiratory rate, O_2 saturation, and temperature) and birthweights were within the normal range. In each of the born twin pairs, one twin lamb was rejected by the ewe and both lambs became dehydrated

within 24 hours of birth. One ewe had obvious mastitis, but the other ewe did not. Despite artificial feeding, the lambs' condition deteriorated and an elective post-mortem examination was performed 2 days after birth on the advice of the veterinary surgeons. There was no evidence of structural abnormality or infection at post-mortem examination of these lambs. The remaining three lambs grew at a normal rate, and survived to scheduled post-mortem examination at 6 months of age.

Long-Term Engraftment in Lambs After In Utero Autologous Transplantation

eGFP+ cells were detected in the peripheral blood of all lambs that survived to birth (mean = 2.72%, range 1.6%– 4.5%, Fig. 6B). In those lambs that survived long-term, the

Animal	CD34+ Cells	Liver	Heart	Muscle	Lung	Kidney	Spleen	Adrenal	Gonad
NSG3	Frozen AF	+	-	-	-	-	-	-	-
NSG4	Frozen AF	+	-	-	-	-	+	-	-
NSG5	Frozen AF	-	-	-	-	-	-	-	-
NSG7	Fresh AF	+	-	-	-	-	+	+	-
NSG8	Fresh AF	+	-	-	-	-	+	-	-
NSG9	Fresh AF	+	-	-	-	-	-	-	-
NSG11	Adult BM	+	-	-	-	-	+	+	-
NSG12	Adult BM	+	-	-	-	-	-	-	-
NSG13	Adult BM	+	-	-	-	-	+	-	-

Figure 4. Engraftment analysis of other organs of primary transplanted NSG mice. (A): The table shows PCR detection of eGFP+ DNA in the tissues of NSG mice transplanted with sheep CD34+eGFP+ cells. Eight out of nine animals showed an eGFP+ signal in the liver, while five out of nine and two out of nine were positive in the spleen and adrenal gland, respectively. Sheep-specific beta-actin was used for the internal control primer. (B): Analysis for engraftment in other hematopoietic tissues. The left panel shows the flow cytometry results. The bar in the graphs shows the percentage of eGFP+ cells in tissues as presented by the small peak located to the right. The right panel shows the summary graphs. Cell sources were frozen AF (light gray), fresh AF (dark gray), and adult BM (black). In the liver, there was a significantly lower percentage of eGFP+ cells after transplantation with the frozen AF cell source when compared with the other two cell sources. There was no difference in spleen engraftment. Error bar: SD, *, $p < .05$. (C): Confocal microscopy shows eGFP+ cells in the liver of transplanted NSG mice. Green: eGFP in the cytoplasm. Blue: DAPI for the nucleus. Bar = 10 μm. (D, E): Immunofluorescence study on a liver section from an NSG mouse transplanted with fresh CD34+eGFP+ AF cells. In the liver, rare cells that costained with eGFP and alpha-fetoprotein (E) were found. Bar = 10 μm. (F): Level of liver engraftment: eGFP+ cells per high power field were counted by three individuals blinded to the study. There was no statistically significant difference between the groups (ANOVA). Abbreviations: AF, amniotic fluid; BM, bone marrow; GFP, green fluorescent protein; NSG, NOD-SCID-gamma.

peripheral blood remained eGFP+ up to scheduled post-mortem examination at 6 months of age (M1-A, M2-B, and M3-A, Fig. 6B). The strength of the eGFP+ signal started to decrease after 4 weeks of age (4 months after in utero injection), but the level of eGFP+ cells in the blood remained steady at around 2% up to 6 months of age. Samples of hematopoietic organs were collected from lambs at birth ($n = 2$) and eGFP+ cells were detected by flow cytometry in the liver (2.9%, 4.3%) and the BM (2.2%, 2.5%). The spleen and thymus were negative for eGFP+ cell engraftment in both lambs. At 6 months of age, BM was collected from the surviving lambs ($n = 3$) from multiple sites (femur, humerus, iliac crest, and sternum) under terminal anesthesia as part of the scheduled post-mortem examination. eGFP+ cells were detected in the BM (mean = 4.05%, range 2.43%–5.47%, Fig. 7A), and also in the peripheral blood and liver (data not shown).

Secondary Xenogeneic Transplantation of AF-Derived Sheep Hematopoietic-Repopulating Cells into NSG Recipient Mice

In order to further confirm the hematopoietic potential of CD34+ AF cells, whole unfractionated BM isolated from the transplanted lambs was transplanted into NSG secondary

recipient mice (3×10^5 cells, $n = 9$, with BM from one lamb being transplanted into three NSG recipients) with 100% survival to scheduled post-mortem examination at 3 months post-transplantation. eGFP+ cells could be detected in the peripheral blood at 1, 2, and 3 months after secondary transplantation (two out of nine mice). At 3 months after secondary transplantation, eGFP+ cells were detected by flow cytometry in the liver, blood, and BM of secondary NSG recipient mice (Fig. 7B, 7C). PCR analysis of hematopoietic tissues also demonstrated eGFP+ DNA in the liver, blood, BM, spleen, and thymus (Fig. 7C).

Discussion

In this study, we have demonstrated that CD34+ cells can be isolated from sheep AF, transduced, and reconstitute hematopoiesis in primary and secondary NSG recipient mice, with evidence of engraftment in multiple hematopoietic organs. In addition, autologous IUSCT of these cells into donor sheep fetuses results in long-term engraftment in the peripheral blood and hematopoietic organs up to the last sampling time of 6 months after birth (9 months post-IUSCT). Finally, transduced cells derived from those animals

A Secondary Transplantation

Figure 5. Analysis of NSG mice after secondary transplantation. **(A):** Flow cytometry analysis of the peripheral blood of secondary NSG mice recipients at 1, 2, and 3 months after transplantation. The BM cell source group (NSG21, NSG22, blue lines) showed higher level of eGFP+ cells in the blood than the frozen AF (red lines) and fresh AF (green lines) cell source groups. No cells were detected in the blood of two animals injected with frozen or fresh AF (NSG16 and NSG20). Control: uninjected animal (gray line). **(B):** Flow cytometry of the hematopoietic organs of NSG mice recipients showing the percentage of eGFP+ cells 3 months after secondary transplantation. Abbreviations: AF, amniotic fluid; BM, bone marrow; GFP, green fluorescent protein.

B

Cells injected	Animal	Blood, 1M	Blood, 2M	Blood, 3M	Liver	Spleen	BM	Thymus
Frozen AF	NSG15	2.27	2.01	2.02	3.15	1.31	2.34	0.43
Frozen AF	NSG16	0.07	0.05	0.09	0.27	0.31	0.41	0.13
Frozen AF	NSG17	2.01	2.28	1.75	2.45	2.12	2.54	0.01
Fresh AF	NSG18	1.71	1.51	1.58	2.69	1.12	1.98	0.32
Fresh AF	NSG19	3.2	2.84	2.62	4.12	2.74	3.12	0.14
Fresh AF	NSG20	0.07	0.09	0.01	0.47	0.21	0.35	0.34
BM	NSG21	5.92	4.21	4.32	4.76	2.55	4.12	0.21
BM	NSG22	3.21	3.45	3.12	4.49	2.34	3.23	0.18
uninjected	Control	0.03	0.08	0.09	0.16	0.24	0.22	0.45

A

		Gestational age (Days)						
Ewe	Lamb	Amniocentesis	Transplantation	Delivery	Postmortem	CD34+ cells injected	injected volume (ml)	MOI
M1	M1-A	60	62	145	6 months	20000	2	50
	M1-B	60	62	*	-	20000	2	50
M2	M2-A	63	65	145	1 day PD	20000	2	50
	M2-B	63	65	145	6 months	20000	2	50
M3	M3-A	63	65	145	6 months	20000	2	50
	M3-B	63	65	145	1 day PD	20000	2	50

B

Figure 6. In utero autologous intraperitoneal transplantation of sheep amniotic fluid CD34+ cells in fetal sheep with long-term follow up. **(A):** Summary of fetal sheep experiments. Ultrasound-guided amniocentesis was used to collect 20 ml of amniotic fluid (AF) from each fetus, and CD34+ cells were selected. After 48 hours of lentivector transduction in vitro, the transduced CD34+AF-derived cells were injected back into the donor fetus by ultrasound-guided intraperitoneal injection. **(B):** Engraftment in the peripheral blood after in utero transplantation of autologous sheep CD34+eGFP+ AF cells. All five born lambs showed eGFP+ cells in the peripheral blood at birth, and all three survivors revealed persistent levels of engraftment of around 2% up to the last sampling point at 6 months of age. Negative control: peripheral blood from uninjected sheep. M1, M2, and M3: the three ewes that showed negativity for eGFP signal. Abbreviation: GFP, green fluorescent protein.

maintained their in vivo hematopoietic potential and showed hematopoietic engraftment when transplanted into NSG recipients.

Our results showed that CD34+ cells isolated from sheep AF and BM possess a similar hematopoietic potential. AF and BM sheep cells isolated using a novel sheep-specific CD34

Figure 7. Secondary xenogeneic transplantation of the BM cells from in utero autologous transplanted lambs into NSG mice. **(A):** Following in utero transplantation of transduced autologous sheep CD34+eGFP+ amniotic fluid cells, lamb BM (*n* = 3) was collected at 6 months of age and was confirmed to be positive for eGFP by flow cytometry. **(B):** These lamb BM samples were transplanted into secondary NSG recipients (xenogeneic transplantation) and flow cytometry of peripheral blood, liver, and BM of these secondary recipients demonstrated eGFP+ cells. Negative control: uninjected lamb BM cells; Positive control: BM cells of YFP transgenic mice. **(C):** Summary table showing results of secondary xenotransplantation of BM from in utero transplanted lambs into NSG recipients. +: positive for eGFP band by PCR; −: negative for eGFP; n/a: not available. Positive control: samples from YFP mice, Negative control: samples from uninjected NSG mouse. Abbreviations: BM, bone marrow; NSG, NOD-SCID-gamma.

		Blood	Liver		BM		Spleen		Thymus	
Lamb	mice ID	flow	PCR	flow	PCR	flow	PCR	flow	PCR	flow
M1-A	1	-	-	3.72	n/a	-	-	-	n/a	-
M1-A	2	-	-	2.78	n/a	-	-	-	-	2.13
M1-A	3	3.74	+	1.37	n/a	-	-	-	+	-
M2-B	4	-	+	8.64	n/a	-	-	-	+	-
M2-B	5	-	+	-	+	-	+	4.15	+	-
M2-B	6	-	n/a	-	n/a	-	+	-	-	-
M3-A	7	-	+	1.05	+	1.01	-	3.69	+	-
M3-A	8	-	+	3.45	+	-	+	7.04	+	-
M3-A	9	1.04	-	2.45	-	-	-	-	n/a	-

antibody were also positive for CD45, but negative for CD31, CD14, CD44, CD58, a hematopoietic phenotype which is in keeping with their potential to form colonies, further proving that the presence of cells in the AF with hematopoietic potential is not limited to mice and humans [13]. After being transduced, cells were transplanted without sorting for two reasons. First, we focused on maximizing cell number since the efficiency of gene transfer achieved in the CD34+ sheep AF or BM cells was relatively high at around 60%. This is higher than that what has been previously reported in human BM-derived MSC, HSC, and embryonic stem cells, in which gene transfer efficiency was 40% [23], 50% [24], and 14%–48% [25], respectively. We have previously shown that human AFS cells can be efficiently transduced using adenoviral vectors [26], and we achieved a similar transduction efficiency using a lentivector in sheep AF-derived MSCs [15]. Lentivectors also have the advantage of allowing sustained transgenic protein expression [27]. Second, we wished to avoid clonal selection of the cells and rather to observe what could happen with minimal cell manipulation.

After primary transplantation into NSG recipients, the hematopoietic potential of these cells was demonstrated using flow cytometry, PCR, and immunostaining, which confirmed that these cells engrafted in most of the hematopoietic organs. CD34+ BM cells tended to have a slightly higher rate of engraftment compared to CD34+ cells derived from frozen AF, but a similar rate to cells derived from fresh AF. This is in keeping with the finding that hematopoietic stem cells could be more sensitive to cryopreservation, as described before for other cell sources such as peripheral blood stem cells [28].

Having demonstrated their hematopoietic potential in NSG mice, we tested whether AF-derived CD34+ stem cells could engraft following autologous IUSCT in sheep. Transduced autologous cells readily migrated from the peritoneal cavity injection site to engraft all the major hematopoietic organs, providing continued transgenic protein (eGFP) expression in multiple fetal organs, the BM, and the peripheral blood. Tissue analysis by PCR, immunofluorescence, and flow cytometry revealed that CD34+ AF or BM cells preferentially engrafted, as expected, in the fetal liver and other hematopoietic organs [29]. Admittedly, the level of tissue engraftment was low, which is likely due to the small number of autologous cells transplanted. For some congenital diseases however, such as severe hemophilia for example, only 1% level of protein expression is required to ameliorate the severe phenotype [30]. Thus, for many congenital diseases, the levels of engraftment we achieved may be sufficient to improve the phenotype or even affect a cure. Increasing the number of cells delivered is likely to lead to improved levels of engraftment. Currently however, expansion of AF stem cells results in the production of committed MSC progenitors, and expansion

while maintaining hematopoietic progenitors has not yet been achieved. Other options for increasing the level of engraftment rate could include targeting the liver with direct injection, resulting in a degree of liver damage that could potentially enhance liver engraftment. Indeed, prior work demonstrated that intrahepatic injection of human MSC into first trimester fetal sheep gave a higher level of engraftment (12.5%), particularly in the parenchyma, when compared with intraperitoneal injection (2.6%), which resulted in higher periportal generation of hepatocytes [31]. A combined injection approach might therefore result in the highest level and broadest distribution of donor-derived hepatocytes. In current clinical practice, however, intraperitoneal injection is the route of choice for fetal transfusion in the first trimester, due to its inherent safety, but improvements in fetal imaging may make first trimester intravascular injection more feasible. Damaging an organ such as the liver or muscle provides a proliferation stimulus for the transplanted stem cells and may create a donor stem cell advantage for engraftment. For example, protocols such as postnatal boosting after irradiation, donor lymphocyte infusion [32, 33], or cotransplantation of major histocompatibility complex (MHC)-matched purified facilitating cells [34] have been used successfully in the fetal mouse to improve engraftment.

A limitation of this study was the lack of data on the fetal and maternal immune response, since we were concentrating on demonstrating hematopoiesis and engraftment. Detailed studies on the immune response comparing autologous with allogeneic and maternal human leukocyte antigen (HLA)-matched IUSCT will be necessary to study immune rejection of in utero transplanted cells.

For clinical translation, demonstration that autologous IUSCT can cure congenital hematopoietic disease long term is required in a large animal model of disease. Our future work aims to test this in a hemophilia A sheep model [35]. Recent data in this model showed that postnatal transplantation with paternal MSCs transduced with a porcine FVIII-encoding lentivector and transplanted via the intraperitoneal route without preconditioning resulted in a phenotypic correction for up to a year after transplantation, but long-term cure was not possible due to the development of antibodies to the porcine FVIII protein [36]. The use of autologous cells and ovine FVIII may avoid this problem. The immune response and safety of IUSCT using transduced autologous AF cells for the fetus and mother will also need to be explored, and suitable vectors developed that produce regulated long-term expression. Ultimately repeated postnatal infusion of transduced autologous AF cells may be required.

CONCLUSIONS

In conclusion, we have shown here for the first time that CD34+ stem cells with hematopoietic potential could be derived from fetal sheep. Besides their capacity to engraft in immunodeficient mice, CD34+ sheep AF cells have potential to be used as a vehicle for gene therapy in an autologous setting.

ACKNOWLEDGMENTS

AUTHOR CONTRIBUTIONS

S.W.S.S.: designed and performed the research, collected, analyzed, and interpreted data, performed statistical analysis, and wrote the manuscript; M.B.: designed and performed the research and collected, analyzed, and interpreted data; C.P., P.S., J.L., and P.M.: collected, analyzed, and interpreted data; M.B.: performed the research and collected data; A.T.: designed the research and interpreted the data; C.D.P. and G.A.-P.: contributed vital new reagents and interpreted the data; A.P. and P.J.C.: analyzed and interpreted the data; A.L.D. and P.de.C.: designed and performed the research, collected, analyzed, and interpreted data, and cowrote the manuscript. A.L.D. and P.D.C. contributed equally to this article.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors indicate no potential conflicts of interest.

REFERENCES

1 Burt RK. Clinical utility in maximizing CD34+ cell count in stem cell grafts. STEM CELLS 1999;17:373–376.

2 Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953;172:603–606.

3 Surbek D, Schoeberlein A, Wagner A. Perinatal stem-cell and gene therapy for hemoglobinopathies. Semin Fetal Neonatal Med 2008;13:282–290.

4 Tiblad E, Westgren M. Fetal stem-cell transplantation. Best Pract Res Clin Obstet Gynaecol 2008;22:189–201.

5 Westgren M, Ringden O, Eik-Nes S et al. Lack of evidence of permanent engraftment after in utero fetal stem cell transplantation in congenital hemoglobinopathies. Transplantation 1996;61:1176–1179.

6 Merianos DJ, Tiblad E, Santore MT et al. Maternal alloantibodies induce a postnatal immune response that limits engraftment following in utero hematopoietic cell transplantation in mice. J Clin Invest 2009;119:2590–2600.

7 Nijagal A, Wegorzewska M, Le T et al. The maternal immune response inhibits the success of in utero hematopoietic cell transplantation. Chimerism 2011;2:55–57.

8 Peranteau WH, Endo M, Adibe OO et al. Evidence for an immune barrier after in utero hematopoietic-cell transplantation. Blood 2007;109:1331–1333.

9 De Coppi P, Bartsch G, Jr., Siddiqui MM et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 2007;25:100–106.

10 Prusa A, Hengstschlager M. Amniotic fluid cells and human stem cell research—a new connection. Signature 2002;8:253–257.

11 Fauza D. Amniotic fluid and placental stem cells. Best Pract Res Clin Obstet Gynaecol 2004;18:877–891.

12 Piccoli M, Franzin C, Bertin E et al. Amniotic fluid stem cells restore the muscle cell niche in a HSA-Cre, Smn(F7/F7) mouse model. STEM CELLS 2012;30:1675–1684.

13 Ditadi A, de Coppi P, Picone O et al. Human and murine amniotic fluid c-Kit+Lin- cells display hematopoietic activity. Blood 2009;113:3953–3960.

14 Galende E, Karakikes I, Edelmann L et al. Amniotic fluid cells are more efficiently

reprogrammed to pluripotency than adult cells. Cell Reprogram 2010;12:117–125.

15 Shaw SW, Bollini S, Nader KA et al. Autologous transplantation of amniotic fluid-derived mesenchymal stem cells into sheep fetuses. Cell Transplant 2011;20:1015–1031.

16 Flake AW, Harrison MR, Adzick NS et al. Transplantation of fetal hematopoietic stem cells in utero: The creation of hematopoietic chimeras. Science 1986;233:776–778.

17 Zanjani ED, Ascensao JL, Flake AW et al. The fetus as an optimal donor and recipient of hemopoietic stem cells. Bone Marrow Transplant 1992;10(suppl 1):107–114.

18 Kawashima I, Zanjani ED, Almaida-Porada G et al. CD34+ human marrow cells that express low levels of Kit protein are enriched for long-term marrow-engrafting cells. Blood 1996;87:4136–4142.

19 Civin CI, Almeida-Porada G, Lee MJ et al. Sustained, retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo. Blood 1996;88:4102–4109.

20 Ziegler BL, Valtieri M, Porada GA et al. KDR receptor: A key marker defining hematopoietic stem cells. Science 1999;285:1553–1558.

21 Porada CD, Harrison-Findik DD, Sanada C et al. Development and characterization of a novel CD34 monoclonal antibody that identifies sheep hematopoietic stem/progenitor cells. Exp Hematol 2008;36:1739–1749.

22 David A, Cook T, Waddington S et al. Ultrasound-guided percutaneous delivery of adenoviral vectors encoding the beta-galactosidase and human factor IX genes to early gestation fetal sheep in utero. Hum Gene Ther 2003;14:353–364.

23 Zhang XY, La Russa VF, Reiser J. Transduction of bone-marrow-derived mesenchymal stem cells by using lentivirus vectors pseudotyped with modified RD114 envelope glycoproteins. J Virol 2004;78:1219–1229.

24 Sutton RE, Wu HT, Rigg R et al. Human immunodeficiency virus type 1 vectors efficiently transduce human hematopoietic stem cells. J Virol 1998;72:5781–5788.

25 Gharwan H, Hirata RK, Wang P et al. Transduction of human embryonic stem cells by foamy virus vectors. Mol Ther 2007;15:1827–1833.

26 Grisafi D, Piccoli M, Pozzobon M et al. High transduction efficiency of human amniotic fluid stem cells mediated by adenovirus vectors. Stem Cells Dev 2008;17:953–962.

27 Philippe S, Sarkis C, Barkats M et al. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci USA 2006;103:17684–17689.

28 Lioznov M, Dellbrugger C, Sputtek A et al. Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM. Bone Marrow Transplant 2008;42:121–128.

29 Almeida-Porada G, Porada C, Gupta N et al. The human-sheep chimeras as a model for human stem cell mobilization and evaluation of hematopoietic grafts' potential. Exp Hematol 2007;35:1594–1600.

30 Waddington SN, Nivsarkar MS, Mistry AR et al. Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. Blood 2004;104:2714–2721.

31 Chamberlain J, Yamagami T, Colletti E et al. Efficient generation of human hepatocytes by the intrahepatic delivery of clonal human mesenchymal stem cells in fetal sheep. Hepatology 2007;46:1935–1945.

32 Hayashi S, Peranteau WH, Shaaban AF et al. Complete allogeneic hematopoietic chimerism achieved by a combined strategy of in utero hematopoietic stem cell transplantation and postnatal donor lymphocyte infusion. Blood 2002;100:804–812.

33 Peranteau WH, Hayashi S, Hsieh M et al. High-level allogeneic chimerism achieved by prenatal tolerance induction and postnatal nonmyeloablative bone marrow transplantation. Blood 2002;100:2225–2234.

34 Gaines BA, Colson YL, Kaufman CL et al. Facilitating cells enable engraftment of purified fetal liver stem cells in allogeneic recipients. Exp Hematol 1996;24:902–913.

35 Porada CD, Sanada C, Long CR et al. Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A. J Thromb Haemost 2010;8:276–285.

36 Porada CD, Sanada C, Kuo CJ et al. Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC. Exp Hematol 2011;39:1124–1135. e1124.